000298172 001__ 298172
000298172 005__ 20250123163405.0
000298172 0247_ $$2doi$$a10.1136/bmjopen-2024-087177
000298172 0247_ $$2pmid$$apmid:39832968
000298172 0247_ $$2pmc$$apmc:PMC11752006
000298172 037__ $$aDKFZ-2025-00191
000298172 041__ $$aEnglish
000298172 082__ $$a610
000298172 1001_ $$00009-0000-0256-0800$$aBoyer, Lisa$$b0
000298172 245__ $$aPreliminary effectiveness of social prescription and virtual patient information in increasing tertiary prevention among cancer patients (ESPRIT): protocol for a single-centre, randomised controlled pilot trial.
000298172 260__ $$aLondon$$bBMJ Publishing Group$$c2025
000298172 3367_ $$2DRIVER$$aarticle
000298172 3367_ $$2DataCite$$aOutput Types/Journal article
000298172 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737629364_10708
000298172 3367_ $$2BibTeX$$aARTICLE
000298172 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298172 3367_ $$00$$2EndNote$$aJournal Article
000298172 520__ $$aTertiary prevention through physical activity and psychosocial support can positively impact patient outcomes, such as physical function and quality of life (QoL). However, more research is required on the effectiveness of strategies designed to increase the uptake of tertiary prevention programmes among cancer patients. Here, we present the protocol for a single-centre, randomised controlled pilot trial testing the preliminary effectiveness of social prescription and virtual patient information in increasing tertiary prevention among cancer patients and support persons (SPs) (ESPRIT 'Effectiveness of a social prescription and virtual patient information in increasing tertiary prevention' pilot trial).Cancer patients attending medical oncology units at a university hospital in southern Germany and their SPs will be randomly allocated as a dyad to group A (social prescription (n=36)), group B (virtual patient information (n=36)) or group C (usual care (n=36)). The hospital is part of a Comprehensive Cancer Centre mainly treating patients living in rural areas. Primary outcomes are the uptake of physical activity, participation in social activities and psychosocial support. Secondary outcomes are overall QoL, knowledge of the health benefits of physical activity and psychosocial support and self-efficacy of patients. The outcomes will be assessed at baseline and after 3, 6 and 12 months of follow-up. Physical activity will be assessed using accelerometers and measured by average steps per day within the last 2 weeks after recruitment and at follow-up visits (3, 6 and 12 months). Cost-effectiveness and the time spent in the consultation, as well as potential implementation barriers and facilitators, will also be explored as part of a mixed-methods hybrid design. All data will be summarised descriptively. Regarding the analysis of primary endpoints, the average number of steps per day, as well as the summary score of the social activity log and self-report on the use of psychosocial support, will be compared between the groups (A, B and C) using analysis of variance, followed by Dunnett's test for pairwise comparisons of the intervention groups against the control group. Mean differences and 95% CIs will be presented as effect estimates. The analysis of secondary endpoints will include appropriate statistical methods such as the χ2 test of independence or linear regression models, which will be used to analyse secondary endpoints and to investigate factors influencing preliminary effectiveness.This trial has been approved by the ethics committee of the University of Regensburg (reference: 23-3317-101). Signed written informed consent is required from all study participants. The results of the study will be used to inform the power calculation for future confirmatory trials and will be submitted for publication.DRKS00033771.
000298172 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000298172 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298172 650_7 $$2Other$$aONCOLOGY
000298172 650_7 $$2Other$$aPatient-Centered Care
000298172 650_7 $$2Other$$aPsychosocial Intervention
000298172 650_7 $$2Other$$aQuality of Life
000298172 650_7 $$2Other$$aSocial Support
000298172 650_2 $$2MeSH$$aHumans
000298172 650_2 $$2MeSH$$aPilot Projects
000298172 650_2 $$2MeSH$$aQuality of Life
000298172 650_2 $$2MeSH$$aNeoplasms: psychology
000298172 650_2 $$2MeSH$$aNeoplasms: prevention & control
000298172 650_2 $$2MeSH$$aExercise
000298172 650_2 $$2MeSH$$aTertiary Prevention: methods
000298172 650_2 $$2MeSH$$aSocial Support
000298172 650_2 $$2MeSH$$aGermany
000298172 650_2 $$2MeSH$$aMale
000298172 650_2 $$2MeSH$$aRandomized Controlled Trials as Topic
000298172 650_2 $$2MeSH$$aFemale
000298172 650_2 $$2MeSH$$aSelf Efficacy
000298172 7001_ $$aBernardi, Christine$$b1
000298172 7001_ $$aLeitzmann, Michael$$b2
000298172 7001_ $$aKoller, Michael$$b3
000298172 7001_ $$aPukrop, Tobias$$b4
000298172 7001_ $$aEinhell, Sabine$$b5
000298172 7001_ $$aHeudobler, Daniel$$b6
000298172 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b7$$udkfz
000298172 7001_ $$aHerr, Wolfgang$$b8
000298172 7001_ $$aHerrmann, Anne$$b9
000298172 773__ $$0PERI:(DE-600)2599832-8$$a10.1136/bmjopen-2024-087177$$gVol. 15, no. 1, p. e087177 -$$n1$$pe087177$$tBMJ open$$v15$$x2044-6055$$y2025
000298172 909CO $$ooai:inrepo02.dkfz.de:298172$$pVDB
000298172 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000298172 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000298172 9141_ $$y2025
000298172 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMJ OPEN : 2022$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-24T13:10:16Z
000298172 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-24T13:10:16Z
000298172 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-01-24T13:10:16Z
000298172 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-19
000298172 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-19
000298172 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000298172 980__ $$ajournal
000298172 980__ $$aVDB
000298172 980__ $$aI:(DE-He78)C110-20160331
000298172 980__ $$aUNRESTRICTED